ArticleBMC geriatrics2026
Vancomycin-induced acute kidney injury in older Chinese patients: a multicenter retrospective cohort study.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundVancomycin-associated nephrotoxicity remains a major clinical concern, yet evidence in older patients is limited and largely derived from small single-center studies. This multicenter study aimed to evaluate the incidence, risk factors, and outcomes of vancomycin-induced acute kidney injury (VI-AKI).
methodsIn this retrospective cohort study, patients aged ≥ 65 years who received vancomycin at three tertiary hospitals in Shanghai between 2009 and 2024 were included. AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Multivariable logistic regression was performed to identify independent risk factors. The primary outcome was VI-AKI incidence; secondary outcomes included renal recovery and all-cause mortality. A predefined subgroup analysis assessed the association between vancomycin trough concentrations and VI-AKI in patients undergoing therapeutic drug monitoring (TDM).
resultsAmong 3,762 patients, VI-AKI occurred in 640 (17.0%). Independent risk factors included age > 75 years, heart failure, baseline renal insufficiency, multiple organ failure, hypoproteinemia, intensive care unit admission, sepsis, vancomycin dose > 2 g/day, and concomitant use of aminoglycosides or piperacillin-tazobactam (all P < 0.05). Complete renal recovery occurred in 21.9% of patients and was less likely in those with stage 3 AKI (OR 0.43, P = 0.012), while acetylcysteine use was associated with a higher likelihood of recovery (OR 2.42, P = 0.009). In the TDM subgroup (n = 433), VI-AKI incidence was 25.9%, and trough concentrations ≥ 17.3 mg/L were independently associated with increased risk (OR 3.02, P < 0.001).
conclusionVI-AKI is common in older adults receiving vancomycin and is associated with multiple clinical and treatment-related factors. The low rate of renal recovery underscores the need for early risk stratification and optimized therapeutic drug monitoring in this population.
trial registrationThis clinical trial was registered in the Chinese Clinical Trial Registry (ChiCTR) with the identifier ChiCTR2400094474 on 23 December 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.